What Does the FDA's Latest PFAS and Cosmetics Crackdown Mean for You in 2026?

The FDA closed out 2025 with a flurry of activity that touches nearly everyone who uses personal care products: a warning letter over manufacturing violations, new guidance on how recalls should work under the Modernization of Cosmetics Regulation Act (MoCRA), continued attention to PFAS data gaps in cosmetics, and word that a hair-growth pill has advanced to Phase III trials. Here's what actually happened, who it affects, and what you can do about it.

What Did the FDA Announce?

According to Cosmetics & Toiletries, the FDA issued a warning letter dated Dec. 18, 2025, to Private Label Skin Care, Inc., citing significant violations of Current Good Manufacturing Practice (CGMP) requirements. The same roundup notes ongoing FDA work on MoCRA recall guidance, continued discussion of gaps in PFAS-related data for cosmetic products, and updates on warning letters and recalls more broadly. Separately, a hair-growth pill has reportedly reached Phase III clinical trials, though that item is a drug-development update rather than a cosmetics safety action.

Who Is Affected by This News?

Three groups should pay attention:

• Consumers who buy skin care and cosmetic products from smaller or private-label brands, since manufacturing violations can affect product quality and consistency.
• Anyone concerned about PFAS ("forever chemicals") in personal care items, because the FDA has acknowledged that data on PFAS in cosmetics remains incomplete, meaning regulators and consumers alike often lack full visibility into which products may contain these substances.
• People following MoCRA implementation, the 2022 law that gave the FDA new authority over cosmetic recalls, facility registration, and safety substantiation. New recall guidance affects how quickly and clearly companies must act when a product is found to be problematic.

Why Does the Warning Letter Matter?

CGMP violations are not necessarily about a specific toxic ingredient — they typically involve how a product is made, tested, and documented. Poor manufacturing controls can mean inconsistent quality, contamination risk, or mislabeling. When the FDA cites "significant violations," it signals the company's internal quality systems fell short of federal expectations, which can undermine consumer trust even if no single ingredient has been proven harmful in that specific case.

Why Are PFAS Data Gaps a Big Deal?

PFAS (per- and polyfluoroalkyl substances) are a large family of synthetic chemicals used in some cosmetics for water resistance, smooth texture, or long-wear performance — think certain foundations, lip products, and waterproof mascaras. Scientific research has associated long-term PFAS exposure with a range of health concerns, including effects on the liver, immune system, and hormone regulation, though researchers caution these are associations observed in studies, not proof that any single product causes harm.

The FDA's acknowledgment of data gaps means the agency itself doesn't have complete information on which products contain PFAS, at what levels, or how consumers are exposed over time. That gap makes it harder for regulators to set enforceable limits and harder for shoppers to know what's actually in their makeup bag. Independent testing and ingredient-list scrutiny remain some of the few tools consumers currently have.

What Does MoCRA Recall Guidance Change?

MoCRA, which phased in over 2023–2025, gave the FDA mandatory recall authority over cosmetics for the first time — previously, recalls were voluntary. New guidance on how recalls should be communicated and executed is meant to close gaps so that when a product is found unsafe or mislabeled, the process for pulling it from shelves and notifying the public is faster and clearer. For consumers, this should eventually mean quicker, more transparent recall notices, though the system is still maturing.

What Should You Do Right Now?

• Check ingredient labels for PFAS-related terms such as "fluoro," "perfluoro," or "PTFE," especially on long-wear or waterproof products.
• Sign up for FDA recall alerts or check the agency's recall database periodically, particularly if you use private-label or smaller-brand skin care products.
• Use independent resources to cross-check products. Our product finder can help you look up specific items, and our methodology page explains how we evaluate PFAS-related claims and data.
• Don't panic over one warning letter. A CGMP citation is a process issue, not automatically a sign that a specific product on your shelf is dangerous — but it's a reason to stay informed about that brand going forward.

Bottom Line

The FDA's early-2026 activity shows an agency actively working through manufacturing enforcement, PFAS data limitations, and recall process improvements — but it also shows how much remains unfinished. Consumers can't yet rely on complete PFAS disclosure in cosmetics, which makes independent verification and label literacy important tools. Products without confirmed PFAS-related issues can be considered lower concern, but that is not the same as a guarantee of safety, since data gaps mean absence of evidence isn't the same as evidence of absence.

Frequently Asked Questions

Does the FDA warning letter mean a specific product is unsafe?

Not necessarily. The warning letter to Private Label Skin Care, Inc. cited CGMP violations, which relate to manufacturing and quality-control processes rather than confirming a specific ingredient caused harm, according to the FDA's action as reported by Cosmetics & Toiletries.

Are PFAS banned in cosmetics?

No nationwide ban exists as of this reporting. The FDA has acknowledged gaps in PFAS data for cosmetic products, meaning enforcement and disclosure rules are still developing at the federal level, even as some states have passed their own restrictions.

What should I do if a product I use gets recalled?

Stop using it, check the FDA's recall notice for specific lot numbers or return instructions, and consult the company's guidance. This article is for general information only and is not medical or legal advice; contact a healthcare provider with health concerns.